A phase I safety study of PF614-MPAR
Latest Information Update: 24 Mar 2025
At a glance
- Drugs PF614 MPAR (Primary)
- Indications Pain
- Focus Adverse reactions
Most Recent Events
- 10 Mar 2025 Status changed from planning to completed.
- 19 Feb 2021 New trial record
- 01 Feb 2021 According to an Ensysce Biosciences media release, the company expects to complete this study in 2021/2022.